Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week Low - What's Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s stock price reached a new 52-week low during trading on Thursday . The company traded as low as $19.47 and last traded at $19.68, with a volume of 12127 shares trading hands. The stock had previously closed at $20.30.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday. They issued an "overweight" rating on the stock. Morgan Stanley started coverage on Bicara Therapeutics in a research note on Tuesday. They issued an "overweight" rating and a $35.00 price objective on the stock. Stifel Nicolaus assumed coverage on Bicara Therapeutics in a research note on Tuesday. They set a "buy" rating and a $47.00 target price for the company. Finally, TD Cowen started coverage on Bicara Therapeutics in a research report on Tuesday. They issued a "buy" rating on the stock.

Bicara Therapeutics Price Performance

Insider Transactions at Bicara Therapeutics

In other news, major shareholder James E. Flynn bought 70,000 shares of the business's stock in a transaction that occurred on Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the purchase, the insider now owns 897,587 shares of the company's stock, valued at $16,156,566. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the firm's stock in a transaction that occurred on Monday, September 16th. The shares were acquired at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the purchase, the director now directly owns 4,303,418 shares in the company, valued at $77,461,524. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder James E. Flynn acquired 70,000 shares of the company's stock in a transaction on Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the purchase, the insider now directly owns 897,587 shares of the company's stock, valued at approximately $16,156,566. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.